Ray Liver Oil (Raja clavata)

Ray liver oil, derived from the thornback ray (Raja clavata), is a marine lipid source containing DHA (up to 6.8g/100g) and EPA (up to 2.3g/100g), alongside tocopherols and a high polyunsaturated fatty acid profile. Unlike well-studied fish oils, no human clinical trials have evaluated its therapeutic efficacy, making it an unvalidated supplement despite its notable fatty acid composition.

Origin & History

Ray Liver Oil is extracted from the liver of Raja clavata (thornback ray), a cartilaginous fish found in Atlantic and Mediterranean waters. The oil is derived from liver tissue rich in lipids through standard extraction processes, yielding a marine oil primarily composed of triglycerides containing polyunsaturated fatty acids.

Historical & Cultural Context

No evidence of traditional medicinal use in any cultural system (folk medicine, Ayurveda, TCM) was identified in available research. Ray liver oil appears to lack historical therapeutic applications.

Health Benefits

• No clinically proven health benefits - no human trials exist
• Contains DHA (up to 6.8g/100g) and EPA (up to 2.3g/100g) - compositional data only, no efficacy studies
• Provides vitamin E as tocopherols - levels vary by season/location, no therapeutic evidence
• Rich source of PUFAs (up to 30% of total lipids) - nutritional composition only
• May contain variable heavy metal levels - safety concerns noted, no established benefits

How It Works

DHA and EPA from ray liver oil are hypothesized to incorporate into phospholipid bilayers, modulating membrane fluidity and attenuating NF-κB-mediated inflammatory signaling by competitively displacing arachidonic acid from COX-2 and LOX enzyme pathways. EPA serves as a substrate for the synthesis of series-3 prostaglandins and series-5 leukotrienes, which exert reduced pro-inflammatory activity compared to arachidonic acid-derived eicosanoids. Tocopherols present in the oil may quench lipid peroxyl radicals via hydrogen donation, protecting PUFAs from oxidative degradation, though these mechanisms remain extrapolated from other marine oils rather than validated in Raja clavata-specific studies.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses exist for Ray Liver Oil from Raja clavata. Research is limited exclusively to compositional analyses examining fatty acid profiles and contaminant levels. No PMIDs are available as no clinical efficacy or safety studies have been conducted.

Clinical Summary

No human clinical trials have been conducted specifically on ray liver oil from Raja clavata, meaning all potential health effects are inferred from its compositional similarity to other marine fish oils. The available data is limited to biochemical characterization studies reporting fatty acid profiles and seasonal variation in PUFA content, with no randomized controlled trials, dose-response studies, or bioavailability assessments in humans. Evidence for omega-3 benefits is borrowed from the broader fish oil literature, which includes large trials such as REDUCE-IT (n=8,179) on EPA and VITAL (n=25,871) on combined DHA/EPA, but these cannot be directly extrapolated to this specific oil. The overall evidence strength for ray liver oil specifically is classified as insufficient, and no regulatory health claims have been established for this ingredient.

Nutritional Profile

Ray liver oil from Raja clavata is a lipid-rich extract with the following documented composition: Total lipids constitute the primary component, with PUFAs comprising up to 30% of total lipids. Omega-3 fatty acids are the dominant bioactive fraction — DHA (docosahexaenoic acid, 22:6n-3) reaches up to 6.8g/100g and EPA (eicosapentaenoic acid, 20:5n-3) up to 2.3g/100g, though concentrations vary significantly by season, geographic location, and specimen age. Vitamin E is present as mixed tocopherols (alpha-, gamma-, and delta-tocopherol isomers), serving primarily as endogenous antioxidants protecting the PUFAs from oxidation; exact concentrations are seasonally variable and not consistently quantified in literature. The oil contains squalene as a minor triterpene component, characteristic of elasmobranch liver oils. Cholesterol is present as the principal sterol. Fat-soluble vitamins A and D are likely present given the organ source, but species-specific quantification for Raja clavata remains limited in published data. Heavy metals including mercury, cadmium, and lead may bioaccumulate in liver tissue at variable concentrations depending on habitat; this represents a documented safety consideration. Protein content is negligible as this is an extracted oil. No fiber or carbohydrates are present. Bioavailability of DHA and EPA from fish liver oils is generally high due to the triglyceride and phospholipid carrier forms, though the specific lipid class distribution in Raja clavata oil has not been thoroughly characterized.

Preparation & Dosage

No clinically studied dosage ranges, standardized forms, or therapeutic protocols have been established due to complete absence of human trials. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

No established synergies - lacks clinical research

Safety & Interactions

Ray liver oil shares the general safety profile of marine-derived omega-3 oils, including a risk of increased bleeding time at higher doses, which is clinically relevant for individuals taking anticoagulants such as warfarin or antiplatelet drugs like aspirin and clopidogrel. High PUFA content makes the oil susceptible to oxidative rancidity, and consumption of oxidized lipids has been associated with pro-inflammatory and cytotoxic effects. Individuals with fish or seafood allergies should avoid this supplement, and its use during pregnancy or lactation is not supported by any safety data specific to Raja clavata liver oil. Potential contaminant load, including heavy metals and fat-soluble environmental pollutants such as PCBs, has not been systematically characterized for this species, representing an unquantified risk.